“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that ...

Researchers have identified enzymes in gut microorganisms that could cleave A and B antigens from red blood, transmuting them to O negative cells.

Cytovale Inc. has posted a feverish run of wins lately. The company gained U.S. FDA clearance for its Intellisep rapid test for sepsis in January 2023, raised $84 million in a series C in November and ...

In the wake of Novo Nordisk’s semaglutide nabbing the title of the U.S.’s biggest blockbuster drug, it’s little surprise that ...

Obesity candidate Maritide (maridebart cafraglutide) took center stage during Amgen Inc.’s first-quarter earnings call after market close May 2, with company executives touting early phase II data and ...

Japanese researchers have transplanted human induced pluripotent stem cells (iPSCs) in a primate model of myocardial infarction and were able to restore heart muscle and function in monkeys. Developed ...

Recent advances in artificial intelligence (AI) have generated a tsunami of popular dystopian musings, but the U.S. Patent ...

Australia is poised to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies ...

Latus Bio Inc. has launched with a focus on developing novel gene therapy candidates for central nervous system (CNS) ...

Kurome Therapeutics Inc. along with the Cincinnati Children’s Hospital Medical Center and U.S. Department of Health and Human Services have patented interleukin-1 receptor-associated kinase (IRAK) and ...

Context Therapeutics Inc. has received FDA clearance of its IND application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.

Shares of Aeon Biopharma Inc. (NYSE:AEON) closed May 3 down $1.66, or 49%, finishing at $1.70 on word that the planned interim analysis of phase II data with ABP-450 (prabotulinumtoxinA) for ...